Ascendis Pharma (ASND) director details warrants and RSUs in Form 3
Rhea-AI Filing Summary
Ascendis Pharma A/S director Lars Holtug has filed an initial statement of beneficial ownership, detailing his equity interests in the company. He reports direct holdings of 4,236 Ordinary Shares, which may be held as American Depositary Shares where each ADS represents one Ordinary Share.
Holtug also holds warrants over 35,000, 7,500, 6,420 and 3,053 underlying Ordinary Shares at exercise prices of 61.0000, 108.0000, 176.2800 and 139.6500 respectively, expiring between November 13, 2028 and December 9, 2031. The warrants are fully vested and currently exercisable.
In addition, he holds restricted stock units covering 1,374, 2,070 and 1,930 underlying Ordinary Shares, each RSU representing a contingent right to receive one ADS. These RSUs vest beginning on March 1, 2027, with some vesting entirely on that date and others in two or three equal annual installments thereafter.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The warrants are fully vested and currently exercisable. The restricted stock units vest on March 1, 2027 and have no expiration date. Each restricted stock unit represents a contingent right to receive one ADS. The restricted stock units vest in two equal annual installments beginning on March 1, 2027. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
